Track topics on Twitter Track topics that are important to you
The industry followed Bayer’s attempts to acquire US agricultural firm Monsanto with fevered anticipation; the takeover eventually closed in September for $66 billion, debt included. Winckworth Sherwood’s Catherine Moss delves into the implications of the biggest deal of 2016.
The flesh of the deal
Original Article: Looking back at the biggest deal of 2016: Bayer-MonsantoNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...